Add to ORKG12th Biennial Meeting of the European-Pharmacology-Society, Tubingen, GERMANY, AUG 31-SEP 03, 2007International audienceno abstrac
The present study was devoted to investigate the effects of the metabotropic glutamate receptor(mGlu...
Parkinson's disease (PD) is characterized by progressive degeneration of dopaminergic neurons of the...
Drugs activating group III metabotropic glutamate receptors (mGluRs) represent therapeutic alternati...
6th International mGluR Meeting, Taormina, ITALY, SEP 14-19, 2008International audienceno abstrac
5th International Meeting on Metabotropic Glutamate Receptors, Taormina, ITALY, SEP 18-23, 2005Inter...
10th Biennial Meeting of the European-Behavioural-Pharmacology-Society, ANTWERP, BELGIUM, SEP 06-09,...
12th Biennial Meeting of the European-Pharmacology-Society, Tubingen, GERMANY, AUG 31-SEP 03, 2007In...
International audienceThe interplay between dopamine and glutamate in the basal ganglia regulate cri...
In recent years there have been tremendous advances in our understanding of the circuitry of the bas...
Parkinson's disease is the slow-progressing chronic neurodegenerative disease. It caused by the prog...
Restoring the balance between excitatory and inhibitory circuits in the basal ganglia, following the...
Parkinson’s disease is characterized by the degeneration of dopaminergic neurons of the substantia n...
Parkinson's disease (PD) is a common neurodegenerative disorder characterized by the loss of dopamin...
In the early sixties, anticholinergic drugs were introduced in the pharmacological treatment of Park...
10th Biennial Meeting of the European-Behavioural-Pharmacology-Society, ANTWERP, BELGIUM, SEP 06-09,...
The present study was devoted to investigate the effects of the metabotropic glutamate receptor(mGlu...
Parkinson's disease (PD) is characterized by progressive degeneration of dopaminergic neurons of the...
Drugs activating group III metabotropic glutamate receptors (mGluRs) represent therapeutic alternati...
6th International mGluR Meeting, Taormina, ITALY, SEP 14-19, 2008International audienceno abstrac
5th International Meeting on Metabotropic Glutamate Receptors, Taormina, ITALY, SEP 18-23, 2005Inter...
10th Biennial Meeting of the European-Behavioural-Pharmacology-Society, ANTWERP, BELGIUM, SEP 06-09,...
12th Biennial Meeting of the European-Pharmacology-Society, Tubingen, GERMANY, AUG 31-SEP 03, 2007In...
International audienceThe interplay between dopamine and glutamate in the basal ganglia regulate cri...
In recent years there have been tremendous advances in our understanding of the circuitry of the bas...
Parkinson's disease is the slow-progressing chronic neurodegenerative disease. It caused by the prog...
Restoring the balance between excitatory and inhibitory circuits in the basal ganglia, following the...
Parkinson’s disease is characterized by the degeneration of dopaminergic neurons of the substantia n...
Parkinson's disease (PD) is a common neurodegenerative disorder characterized by the loss of dopamin...
In the early sixties, anticholinergic drugs were introduced in the pharmacological treatment of Park...
10th Biennial Meeting of the European-Behavioural-Pharmacology-Society, ANTWERP, BELGIUM, SEP 06-09,...
The present study was devoted to investigate the effects of the metabotropic glutamate receptor(mGlu...
Parkinson's disease (PD) is characterized by progressive degeneration of dopaminergic neurons of the...
Drugs activating group III metabotropic glutamate receptors (mGluRs) represent therapeutic alternati...